mor-14 has been researched along with Cardiovascular Stroke in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, M; Fujiwara, H; Fujiwara, T; Higashioka, M; Kariya, T; Minatoguchi, S; Takatsu, H; Takemura, G; Uno, Y; Yoshikuni, Y | 1 |
| Arai, M; Fujiwara, H; Fujiwara, T; Hashimoto, K; Higashioka, M; Kumada, H; Kuwano, K; Minatoguchi, S; Nishida, Y; Takemura, G; Uno, Y; Wang, N | 1 |
| Arai, M; Fujiwara, H; Fujiwara, T; Hashimoto, K; Hashimoto, Y; Minatoguchi, S; Nishida, Y; Takemura, G; Uno, Y; Wang, N; Wu, DJ | 1 |
3 other study(ies) available for mor-14 and Cardiovascular Stroke
| Article | Year |
|---|---|
N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly reduced infarct size in rabbit hearts.
Topics: 1-Deoxynojirimycin; Animals; Collateral Circulation; Enzyme Inhibitors; Glycogen; Glycoside Hydrolase Inhibitors; Hemodynamics; Lactic Acid; Male; Molecular Structure; Myocardial Infarction; Rabbits; Risk Factors | 1998 |
Role of protein kinase C in the reduction of infarct size by N-methyl-1-deoxynojirimycin, an alpha-1,6-glucosidase inhibitor.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Biological Transport; Enzyme Inhibitors; Glycogen; Glycoside Hydrolase Inhibitors; Isoenzymes; Lactates; Male; Myocardial Infarction; Myocardium; Protein Kinase C; Rabbits; Time Factors | 2001 |
Combination of N-methyl-1-deoxynojirimycin and ischemic preconditioning markedly reduces the size of myocardial infarcts in rabbits.
Topics: 1-Deoxynojirimycin; Animals; Combined Modality Therapy; Disease Models, Animal; Enzyme Inhibitors; Glycogen; Glycoside Hydrolase Inhibitors; Heart Ventricles; Ischemia; Ischemic Preconditioning, Myocardial; Lactic Acid; Myocardial Infarction; Rabbits | 2001 |